nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—SLCO1B3—Methotrexate—urinary bladder cancer	0.186	0.327	CbGbCtD
Valsartan—SLCO1B1—Methotrexate—urinary bladder cancer	0.108	0.191	CbGbCtD
Valsartan—ALB—Fluorouracil—urinary bladder cancer	0.107	0.189	CbGbCtD
Valsartan—ALB—Methotrexate—urinary bladder cancer	0.0592	0.104	CbGbCtD
Valsartan—CYP2C9—Fluorouracil—urinary bladder cancer	0.0579	0.102	CbGbCtD
Valsartan—CYP2C9—Cisplatin—urinary bladder cancer	0.0492	0.0866	CbGbCtD
Valsartan—Losartan—UGT2B7—urinary bladder cancer	0.00539	1	CrCbGaD
Valsartan—CYP2C9—urine—urinary bladder cancer	0.00383	0.161	CbGeAlD
Valsartan—AGTR1—prostate gland—urinary bladder cancer	0.00286	0.12	CbGeAlD
Valsartan—SLCO1B3—vagina—urinary bladder cancer	0.00232	0.0978	CbGeAlD
Valsartan—AGTR1—epithelium—urinary bladder cancer	0.0021	0.0883	CbGeAlD
Valsartan—AGTR1—smooth muscle tissue—urinary bladder cancer	0.00202	0.0851	CbGeAlD
Valsartan—AGTR1—renal system—urinary bladder cancer	0.00195	0.0819	CbGeAlD
Valsartan—SLCO1B1—renal system—urinary bladder cancer	0.00186	0.0781	CbGeAlD
Valsartan—AGTR1—female reproductive system—urinary bladder cancer	0.00156	0.0656	CbGeAlD
Valsartan—SLCO1B1—female reproductive system—urinary bladder cancer	0.00149	0.0626	CbGeAlD
Valsartan—AGTR1—vagina—urinary bladder cancer	0.00141	0.0593	CbGeAlD
Valsartan—AGTR1—lymph node—urinary bladder cancer	0.000912	0.0384	CbGeAlD
Valsartan—CYP2C9—female reproductive system—urinary bladder cancer	0.000751	0.0316	CbGeAlD
Valsartan—ALB—lymph node—urinary bladder cancer	0.000703	0.0296	CbGeAlD
Valsartan—Infestation—Methotrexate—urinary bladder cancer	0.000479	0.00123	CcSEcCtD
Valsartan—Hypotension—Etoposide—urinary bladder cancer	0.000476	0.00123	CcSEcCtD
Valsartan—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000474	0.00122	CcSEcCtD
Valsartan—Renal failure—Methotrexate—urinary bladder cancer	0.000471	0.00121	CcSEcCtD
Valsartan—Neutropenia—Epirubicin—urinary bladder cancer	0.00047	0.00121	CcSEcCtD
Valsartan—Dizziness—Thiotepa—urinary bladder cancer	0.000469	0.00121	CcSEcCtD
Valsartan—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000467	0.0012	CcSEcCtD
Valsartan—Urticaria—Fluorouracil—urinary bladder cancer	0.000466	0.0012	CcSEcCtD
Valsartan—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000459	0.00118	CcSEcCtD
Valsartan—Paraesthesia—Etoposide—urinary bladder cancer	0.000458	0.00118	CcSEcCtD
Valsartan—Dyspnoea—Etoposide—urinary bladder cancer	0.000454	0.00117	CcSEcCtD
Valsartan—Somnolence—Etoposide—urinary bladder cancer	0.000453	0.00117	CcSEcCtD
Valsartan—Epistaxis—Methotrexate—urinary bladder cancer	0.000451	0.00116	CcSEcCtD
Valsartan—Vomiting—Thiotepa—urinary bladder cancer	0.000451	0.00116	CcSEcCtD
Valsartan—Infestation—Epirubicin—urinary bladder cancer	0.000448	0.00115	CcSEcCtD
Valsartan—Infestation NOS—Epirubicin—urinary bladder cancer	0.000448	0.00115	CcSEcCtD
Valsartan—Rash—Thiotepa—urinary bladder cancer	0.000447	0.00115	CcSEcCtD
Valsartan—Bronchitis—Doxorubicin—urinary bladder cancer	0.000447	0.00115	CcSEcCtD
Valsartan—Dermatitis—Thiotepa—urinary bladder cancer	0.000447	0.00115	CcSEcCtD
Valsartan—Headache—Thiotepa—urinary bladder cancer	0.000444	0.00115	CcSEcCtD
Valsartan—Decreased appetite—Etoposide—urinary bladder cancer	0.000443	0.00114	CcSEcCtD
Valsartan—Renal failure—Epirubicin—urinary bladder cancer	0.00044	0.00113	CcSEcCtD
Valsartan—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00044	0.00113	CcSEcCtD
Valsartan—Fatigue—Etoposide—urinary bladder cancer	0.000439	0.00113	CcSEcCtD
Valsartan—Constipation—Etoposide—urinary bladder cancer	0.000436	0.00112	CcSEcCtD
Valsartan—Neutropenia—Doxorubicin—urinary bladder cancer	0.000435	0.00112	CcSEcCtD
Valsartan—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000432	0.00111	CcSEcCtD
Valsartan—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000432	0.00111	CcSEcCtD
Valsartan—Haemoglobin—Methotrexate—urinary bladder cancer	0.000432	0.00111	CcSEcCtD
Valsartan—Hepatitis—Methotrexate—urinary bladder cancer	0.00043	0.00111	CcSEcCtD
Valsartan—Haemorrhage—Methotrexate—urinary bladder cancer	0.00043	0.00111	CcSEcCtD
Valsartan—Asthenia—Gemcitabine—urinary bladder cancer	0.000428	0.0011	CcSEcCtD
Valsartan—Pharyngitis—Methotrexate—urinary bladder cancer	0.000426	0.0011	CcSEcCtD
Valsartan—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000424	0.00109	CcSEcCtD
Valsartan—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000424	0.00109	CcSEcCtD
Valsartan—Epistaxis—Epirubicin—urinary bladder cancer	0.000423	0.00109	CcSEcCtD
Valsartan—Pruritus—Gemcitabine—urinary bladder cancer	0.000422	0.00109	CcSEcCtD
Valsartan—Nausea—Thiotepa—urinary bladder cancer	0.000421	0.00109	CcSEcCtD
Valsartan—Urethral disorder—Methotrexate—urinary bladder cancer	0.000421	0.00109	CcSEcCtD
Valsartan—Sinusitis—Epirubicin—urinary bladder cancer	0.00042	0.00108	CcSEcCtD
Valsartan—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000417	0.00107	CcSEcCtD
Valsartan—Pruritus—Fluorouracil—urinary bladder cancer	0.000415	0.00107	CcSEcCtD
Valsartan—Infestation—Doxorubicin—urinary bladder cancer	0.000414	0.00107	CcSEcCtD
Valsartan—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000414	0.00107	CcSEcCtD
Valsartan—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00041	0.00106	CcSEcCtD
Valsartan—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000408	0.00105	CcSEcCtD
Valsartan—Renal failure—Doxorubicin—urinary bladder cancer	0.000407	0.00105	CcSEcCtD
Valsartan—Urticaria—Etoposide—urinary bladder cancer	0.000405	0.00104	CcSEcCtD
Valsartan—Haemoglobin—Epirubicin—urinary bladder cancer	0.000404	0.00104	CcSEcCtD
Valsartan—Rhinitis—Epirubicin—urinary bladder cancer	0.000403	0.00104	CcSEcCtD
Valsartan—Abdominal pain—Etoposide—urinary bladder cancer	0.000403	0.00104	CcSEcCtD
Valsartan—Haemorrhage—Epirubicin—urinary bladder cancer	0.000402	0.00104	CcSEcCtD
Valsartan—Hepatitis—Epirubicin—urinary bladder cancer	0.000402	0.00104	CcSEcCtD
Valsartan—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000402	0.00103	CcSEcCtD
Valsartan—Asthenia—Cisplatin—urinary bladder cancer	0.000399	0.00103	CcSEcCtD
Valsartan—Pharyngitis—Epirubicin—urinary bladder cancer	0.000399	0.00103	CcSEcCtD
Valsartan—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000399	0.00103	CcSEcCtD
Valsartan—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000397	0.00102	CcSEcCtD
Valsartan—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000395	0.00102	CcSEcCtD
Valsartan—Urethral disorder—Epirubicin—urinary bladder cancer	0.000394	0.00102	CcSEcCtD
Valsartan—Epistaxis—Doxorubicin—urinary bladder cancer	0.000391	0.00101	CcSEcCtD
Valsartan—Angiopathy—Methotrexate—urinary bladder cancer	0.00039	0.001	CcSEcCtD
Valsartan—Sinusitis—Doxorubicin—urinary bladder cancer	0.000389	0.001	CcSEcCtD
Valsartan—Immune system disorder—Methotrexate—urinary bladder cancer	0.000388	0.001	CcSEcCtD
Valsartan—Dizziness—Fluorouracil—urinary bladder cancer	0.000388	0.001	CcSEcCtD
Valsartan—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000387	0.000998	CcSEcCtD
Valsartan—Diarrhoea—Cisplatin—urinary bladder cancer	0.000381	0.000981	CcSEcCtD
Valsartan—Alopecia—Methotrexate—urinary bladder cancer	0.00038	0.000979	CcSEcCtD
Valsartan—Vomiting—Gemcitabine—urinary bladder cancer	0.000379	0.000978	CcSEcCtD
Valsartan—Mental disorder—Methotrexate—urinary bladder cancer	0.000376	0.00097	CcSEcCtD
Valsartan—Rash—Gemcitabine—urinary bladder cancer	0.000376	0.00097	CcSEcCtD
Valsartan—Dermatitis—Gemcitabine—urinary bladder cancer	0.000376	0.000969	CcSEcCtD
Valsartan—Hypersensitivity—Etoposide—urinary bladder cancer	0.000376	0.000968	CcSEcCtD
Valsartan—Malnutrition—Methotrexate—urinary bladder cancer	0.000374	0.000964	CcSEcCtD
Valsartan—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000374	0.000964	CcSEcCtD
Valsartan—Headache—Gemcitabine—urinary bladder cancer	0.000374	0.000964	CcSEcCtD
Valsartan—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000373	0.000962	CcSEcCtD
Valsartan—Vomiting—Fluorouracil—urinary bladder cancer	0.000373	0.000962	CcSEcCtD
Valsartan—Rhinitis—Doxorubicin—urinary bladder cancer	0.000373	0.000961	CcSEcCtD
Valsartan—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000372	0.000959	CcSEcCtD
Valsartan—Hepatitis—Doxorubicin—urinary bladder cancer	0.000372	0.000959	CcSEcCtD
Valsartan—Rash—Fluorouracil—urinary bladder cancer	0.00037	0.000954	CcSEcCtD
Valsartan—Dermatitis—Fluorouracil—urinary bladder cancer	0.00037	0.000953	CcSEcCtD
Valsartan—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000369	0.000952	CcSEcCtD
Valsartan—Headache—Fluorouracil—urinary bladder cancer	0.000368	0.000947	CcSEcCtD
Valsartan—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000367	0.000947	CcSEcCtD
Valsartan—Dysgeusia—Methotrexate—urinary bladder cancer	0.000366	0.000944	CcSEcCtD
Valsartan—Asthenia—Etoposide—urinary bladder cancer	0.000366	0.000942	CcSEcCtD
Valsartan—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000366	0.000942	CcSEcCtD
Valsartan—Angiopathy—Epirubicin—urinary bladder cancer	0.000365	0.00094	CcSEcCtD
Valsartan—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000365	0.00094	CcSEcCtD
Valsartan—Immune system disorder—Epirubicin—urinary bladder cancer	0.000363	0.000936	CcSEcCtD
Valsartan—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000362	0.000934	CcSEcCtD
Valsartan—Back pain—Methotrexate—urinary bladder cancer	0.000362	0.000932	CcSEcCtD
Valsartan—Pruritus—Etoposide—urinary bladder cancer	0.000361	0.000929	CcSEcCtD
Valsartan—Alopecia—Epirubicin—urinary bladder cancer	0.000355	0.000916	CcSEcCtD
Valsartan—Nausea—Gemcitabine—urinary bladder cancer	0.000355	0.000914	CcSEcCtD
Valsartan—Vomiting—Cisplatin—urinary bladder cancer	0.000354	0.000912	CcSEcCtD
Valsartan—Vision blurred—Methotrexate—urinary bladder cancer	0.000353	0.000909	CcSEcCtD
Valsartan—Mental disorder—Epirubicin—urinary bladder cancer	0.000352	0.000908	CcSEcCtD
Valsartan—Rash—Cisplatin—urinary bladder cancer	0.000351	0.000904	CcSEcCtD
Valsartan—Dermatitis—Cisplatin—urinary bladder cancer	0.00035	0.000903	CcSEcCtD
Valsartan—Malnutrition—Epirubicin—urinary bladder cancer	0.00035	0.000902	CcSEcCtD
Valsartan—Diarrhoea—Etoposide—urinary bladder cancer	0.000349	0.000899	CcSEcCtD
Valsartan—Nausea—Fluorouracil—urinary bladder cancer	0.000349	0.000898	CcSEcCtD
Valsartan—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000345	0.00089	CcSEcCtD
Valsartan—Flatulence—Epirubicin—urinary bladder cancer	0.000345	0.000889	CcSEcCtD
Valsartan—Dysgeusia—Epirubicin—urinary bladder cancer	0.000343	0.000883	CcSEcCtD
Valsartan—Back pain—Epirubicin—urinary bladder cancer	0.000339	0.000873	CcSEcCtD
Valsartan—Angiopathy—Doxorubicin—urinary bladder cancer	0.000338	0.00087	CcSEcCtD
Valsartan—Dizziness—Etoposide—urinary bladder cancer	0.000337	0.000869	CcSEcCtD
Valsartan—Muscle spasms—Epirubicin—urinary bladder cancer	0.000337	0.000867	CcSEcCtD
Valsartan—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000336	0.000866	CcSEcCtD
Valsartan—Vertigo—Methotrexate—urinary bladder cancer	0.000336	0.000866	CcSEcCtD
Valsartan—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000335	0.000864	CcSEcCtD
Valsartan—Nausea—Cisplatin—urinary bladder cancer	0.00033	0.000852	CcSEcCtD
Valsartan—Vision blurred—Epirubicin—urinary bladder cancer	0.00033	0.00085	CcSEcCtD
Valsartan—Alopecia—Doxorubicin—urinary bladder cancer	0.000329	0.000847	CcSEcCtD
Valsartan—Cough—Methotrexate—urinary bladder cancer	0.000326	0.000841	CcSEcCtD
Valsartan—Mental disorder—Doxorubicin—urinary bladder cancer	0.000326	0.00084	CcSEcCtD
Valsartan—Vomiting—Etoposide—urinary bladder cancer	0.000324	0.000835	CcSEcCtD
Valsartan—Malnutrition—Doxorubicin—urinary bladder cancer	0.000324	0.000835	CcSEcCtD
Valsartan—Rash—Etoposide—urinary bladder cancer	0.000321	0.000828	CcSEcCtD
Valsartan—Dermatitis—Etoposide—urinary bladder cancer	0.000321	0.000827	CcSEcCtD
Valsartan—Headache—Etoposide—urinary bladder cancer	0.000319	0.000823	CcSEcCtD
Valsartan—Flatulence—Doxorubicin—urinary bladder cancer	0.000319	0.000823	CcSEcCtD
Valsartan—Chest pain—Methotrexate—urinary bladder cancer	0.000318	0.000821	CcSEcCtD
Valsartan—Myalgia—Methotrexate—urinary bladder cancer	0.000318	0.000821	CcSEcCtD
Valsartan—Arthralgia—Methotrexate—urinary bladder cancer	0.000318	0.000821	CcSEcCtD
Valsartan—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000317	0.000817	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000316	0.000815	CcSEcCtD
Valsartan—Vertigo—Epirubicin—urinary bladder cancer	0.000315	0.000811	CcSEcCtD
Valsartan—Syncope—Epirubicin—urinary bladder cancer	0.000314	0.000809	CcSEcCtD
Valsartan—Back pain—Doxorubicin—urinary bladder cancer	0.000313	0.000807	CcSEcCtD
Valsartan—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000311	0.000803	CcSEcCtD
Valsartan—Palpitations—Epirubicin—urinary bladder cancer	0.000309	0.000797	CcSEcCtD
Valsartan—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000308	0.000793	CcSEcCtD
Valsartan—Cough—Epirubicin—urinary bladder cancer	0.000305	0.000787	CcSEcCtD
Valsartan—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000305	0.000787	CcSEcCtD
Valsartan—Vision blurred—Doxorubicin—urinary bladder cancer	0.000305	0.000787	CcSEcCtD
Valsartan—Infection—Methotrexate—urinary bladder cancer	0.000303	0.000782	CcSEcCtD
Valsartan—Nausea—Etoposide—urinary bladder cancer	0.000303	0.00078	CcSEcCtD
Valsartan—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000299	0.000772	CcSEcCtD
Valsartan—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000299	0.00077	CcSEcCtD
Valsartan—Chest pain—Epirubicin—urinary bladder cancer	0.000298	0.000768	CcSEcCtD
Valsartan—Arthralgia—Epirubicin—urinary bladder cancer	0.000298	0.000768	CcSEcCtD
Valsartan—Myalgia—Epirubicin—urinary bladder cancer	0.000298	0.000768	CcSEcCtD
Valsartan—Anxiety—Epirubicin—urinary bladder cancer	0.000297	0.000765	CcSEcCtD
Valsartan—Skin disorder—Methotrexate—urinary bladder cancer	0.000297	0.000764	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000296	0.000763	CcSEcCtD
Valsartan—Dry mouth—Epirubicin—urinary bladder cancer	0.000291	0.000751	CcSEcCtD
Valsartan—Vertigo—Doxorubicin—urinary bladder cancer	0.000291	0.00075	CcSEcCtD
Valsartan—Anorexia—Methotrexate—urinary bladder cancer	0.000291	0.00075	CcSEcCtD
Valsartan—Syncope—Doxorubicin—urinary bladder cancer	0.00029	0.000749	CcSEcCtD
Valsartan—Palpitations—Doxorubicin—urinary bladder cancer	0.000286	0.000738	CcSEcCtD
Valsartan—Oedema—Epirubicin—urinary bladder cancer	0.000286	0.000736	CcSEcCtD
Valsartan—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000286	0.000736	CcSEcCtD
Valsartan—Hypotension—Methotrexate—urinary bladder cancer	0.000285	0.000735	CcSEcCtD
Valsartan—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000285	0.000734	CcSEcCtD
Valsartan—Infection—Epirubicin—urinary bladder cancer	0.000284	0.000731	CcSEcCtD
Valsartan—Cough—Doxorubicin—urinary bladder cancer	0.000283	0.000728	CcSEcCtD
Valsartan—Shock—Epirubicin—urinary bladder cancer	0.000281	0.000724	CcSEcCtD
Valsartan—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00028	0.000722	CcSEcCtD
Valsartan—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.00028	0.000721	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000278	0.000717	CcSEcCtD
Valsartan—Skin disorder—Epirubicin—urinary bladder cancer	0.000278	0.000715	CcSEcCtD
Valsartan—Insomnia—Methotrexate—urinary bladder cancer	0.000276	0.000712	CcSEcCtD
Valsartan—Chest pain—Doxorubicin—urinary bladder cancer	0.000276	0.000711	CcSEcCtD
Valsartan—Arthralgia—Doxorubicin—urinary bladder cancer	0.000276	0.000711	CcSEcCtD
Valsartan—Myalgia—Doxorubicin—urinary bladder cancer	0.000276	0.000711	CcSEcCtD
Valsartan—Anxiety—Doxorubicin—urinary bladder cancer	0.000275	0.000708	CcSEcCtD
Valsartan—Paraesthesia—Methotrexate—urinary bladder cancer	0.000274	0.000706	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000274	0.000706	CcSEcCtD
Valsartan—Anorexia—Epirubicin—urinary bladder cancer	0.000272	0.000702	CcSEcCtD
Valsartan—Dyspnoea—Methotrexate—urinary bladder cancer	0.000272	0.000701	CcSEcCtD
Valsartan—Somnolence—Methotrexate—urinary bladder cancer	0.000271	0.000699	CcSEcCtD
Valsartan—Dry mouth—Doxorubicin—urinary bladder cancer	0.00027	0.000695	CcSEcCtD
Valsartan—Dyspepsia—Methotrexate—urinary bladder cancer	0.000269	0.000693	CcSEcCtD
Valsartan—Hypotension—Epirubicin—urinary bladder cancer	0.000267	0.000688	CcSEcCtD
Valsartan—Decreased appetite—Methotrexate—urinary bladder cancer	0.000265	0.000684	CcSEcCtD
Valsartan—Oedema—Doxorubicin—urinary bladder cancer	0.000264	0.000681	CcSEcCtD
Valsartan—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000264	0.000681	CcSEcCtD
Valsartan—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000264	0.000679	CcSEcCtD
Valsartan—Fatigue—Methotrexate—urinary bladder cancer	0.000263	0.000678	CcSEcCtD
Valsartan—Infection—Doxorubicin—urinary bladder cancer	0.000263	0.000677	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00026	0.000671	CcSEcCtD
Valsartan—Shock—Doxorubicin—urinary bladder cancer	0.00026	0.00067	CcSEcCtD
Valsartan—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000259	0.000668	CcSEcCtD
Valsartan—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000259	0.000667	CcSEcCtD
Valsartan—Insomnia—Epirubicin—urinary bladder cancer	0.000258	0.000666	CcSEcCtD
Valsartan—Skin disorder—Doxorubicin—urinary bladder cancer	0.000257	0.000662	CcSEcCtD
Valsartan—Paraesthesia—Epirubicin—urinary bladder cancer	0.000257	0.000661	CcSEcCtD
Valsartan—Dyspnoea—Epirubicin—urinary bladder cancer	0.000255	0.000656	CcSEcCtD
Valsartan—Somnolence—Epirubicin—urinary bladder cancer	0.000254	0.000655	CcSEcCtD
Valsartan—Anorexia—Doxorubicin—urinary bladder cancer	0.000252	0.000649	CcSEcCtD
Valsartan—Dyspepsia—Epirubicin—urinary bladder cancer	0.000251	0.000648	CcSEcCtD
Valsartan—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00025	0.000643	CcSEcCtD
Valsartan—Decreased appetite—Epirubicin—urinary bladder cancer	0.000248	0.00064	CcSEcCtD
Valsartan—Hypotension—Doxorubicin—urinary bladder cancer	0.000247	0.000637	CcSEcCtD
Valsartan—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000247	0.000636	CcSEcCtD
Valsartan—Fatigue—Epirubicin—urinary bladder cancer	0.000246	0.000635	CcSEcCtD
Valsartan—Constipation—Epirubicin—urinary bladder cancer	0.000244	0.00063	CcSEcCtD
Valsartan—Urticaria—Methotrexate—urinary bladder cancer	0.000243	0.000625	CcSEcCtD
Valsartan—Abdominal pain—Methotrexate—urinary bladder cancer	0.000241	0.000622	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000241	0.000621	CcSEcCtD
Valsartan—Insomnia—Doxorubicin—urinary bladder cancer	0.000239	0.000616	CcSEcCtD
Valsartan—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000237	0.000612	CcSEcCtD
Valsartan—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000236	0.000607	CcSEcCtD
Valsartan—Somnolence—Doxorubicin—urinary bladder cancer	0.000235	0.000606	CcSEcCtD
Valsartan—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000234	0.000602	CcSEcCtD
Valsartan—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000233	0.0006	CcSEcCtD
Valsartan—Decreased appetite—Doxorubicin—urinary bladder cancer	0.00023	0.000592	CcSEcCtD
Valsartan—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000228	0.000588	CcSEcCtD
Valsartan—Fatigue—Doxorubicin—urinary bladder cancer	0.000228	0.000587	CcSEcCtD
Valsartan—Urticaria—Epirubicin—urinary bladder cancer	0.000227	0.000585	CcSEcCtD
Valsartan—Constipation—Doxorubicin—urinary bladder cancer	0.000226	0.000583	CcSEcCtD
Valsartan—Abdominal pain—Epirubicin—urinary bladder cancer	0.000226	0.000582	CcSEcCtD
Valsartan—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000225	0.00058	CcSEcCtD
Valsartan—Asthenia—Methotrexate—urinary bladder cancer	0.000219	0.000564	CcSEcCtD
Valsartan—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000216	0.000557	CcSEcCtD
Valsartan—Pruritus—Methotrexate—urinary bladder cancer	0.000216	0.000557	CcSEcCtD
Valsartan—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00021	0.000542	CcSEcCtD
Valsartan—Urticaria—Doxorubicin—urinary bladder cancer	0.00021	0.000541	CcSEcCtD
Valsartan—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000209	0.000539	CcSEcCtD
Valsartan—Diarrhoea—Methotrexate—urinary bladder cancer	0.000209	0.000538	CcSEcCtD
Valsartan—Asthenia—Epirubicin—urinary bladder cancer	0.000205	0.000528	CcSEcCtD
Valsartan—Pruritus—Epirubicin—urinary bladder cancer	0.000202	0.000521	CcSEcCtD
Valsartan—Dizziness—Methotrexate—urinary bladder cancer	0.000202	0.00052	CcSEcCtD
Valsartan—Diarrhoea—Epirubicin—urinary bladder cancer	0.000195	0.000504	CcSEcCtD
Valsartan—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000195	0.000502	CcSEcCtD
Valsartan—Vomiting—Methotrexate—urinary bladder cancer	0.000194	0.0005	CcSEcCtD
Valsartan—Rash—Methotrexate—urinary bladder cancer	0.000192	0.000496	CcSEcCtD
Valsartan—Dermatitis—Methotrexate—urinary bladder cancer	0.000192	0.000496	CcSEcCtD
Valsartan—Headache—Methotrexate—urinary bladder cancer	0.000191	0.000493	CcSEcCtD
Valsartan—Asthenia—Doxorubicin—urinary bladder cancer	0.00019	0.000489	CcSEcCtD
Valsartan—Dizziness—Epirubicin—urinary bladder cancer	0.000189	0.000487	CcSEcCtD
Valsartan—Pruritus—Doxorubicin—urinary bladder cancer	0.000187	0.000482	CcSEcCtD
Valsartan—Vomiting—Epirubicin—urinary bladder cancer	0.000182	0.000468	CcSEcCtD
Valsartan—Nausea—Methotrexate—urinary bladder cancer	0.000181	0.000467	CcSEcCtD
Valsartan—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000181	0.000466	CcSEcCtD
Valsartan—Rash—Epirubicin—urinary bladder cancer	0.00018	0.000464	CcSEcCtD
Valsartan—Dermatitis—Epirubicin—urinary bladder cancer	0.00018	0.000464	CcSEcCtD
Valsartan—Headache—Epirubicin—urinary bladder cancer	0.000179	0.000461	CcSEcCtD
Valsartan—Dizziness—Doxorubicin—urinary bladder cancer	0.000175	0.000451	CcSEcCtD
Valsartan—Nausea—Epirubicin—urinary bladder cancer	0.00017	0.000437	CcSEcCtD
Valsartan—Vomiting—Doxorubicin—urinary bladder cancer	0.000168	0.000433	CcSEcCtD
Valsartan—Rash—Doxorubicin—urinary bladder cancer	0.000167	0.00043	CcSEcCtD
Valsartan—Dermatitis—Doxorubicin—urinary bladder cancer	0.000167	0.000429	CcSEcCtD
Valsartan—Headache—Doxorubicin—urinary bladder cancer	0.000166	0.000427	CcSEcCtD
Valsartan—Nausea—Doxorubicin—urinary bladder cancer	0.000157	0.000405	CcSEcCtD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000119	0.00767	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—CXCL8—urinary bladder cancer	0.000119	0.00766	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.000118	0.00762	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.000118	0.00762	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000117	0.00752	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL2—urinary bladder cancer	0.000114	0.00732	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000108	0.00697	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000107	0.00688	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000107	0.00687	CbGpPWpGaD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000104	0.00669	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—SOD2—urinary bladder cancer	0.000104	0.00669	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	9.93e-05	0.0064	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	9.73e-05	0.00628	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	9.6e-05	0.00619	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	9.23e-05	0.00595	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—MTHFR—urinary bladder cancer	9.13e-05	0.00589	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—SOD2—urinary bladder cancer	8.44e-05	0.00544	CbGpPWpGaD
Valsartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	8.38e-05	0.00541	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—TNF—urinary bladder cancer	8.27e-05	0.00533	CbGpPWpGaD
Valsartan—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	8.23e-05	0.00531	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	8.09e-05	0.00522	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—GPX1—urinary bladder cancer	8.05e-05	0.00519	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	7.99e-05	0.00515	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—MTHFR—urinary bladder cancer	7.43e-05	0.00479	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTZ1—urinary bladder cancer	6.78e-05	0.00437	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—SOD2—urinary bladder cancer	6.7e-05	0.00432	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	6.67e-05	0.0043	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	6.47e-05	0.00418	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTO2—urinary bladder cancer	6.43e-05	0.00415	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NAT1—urinary bladder cancer	6.43e-05	0.00415	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—GPX1—urinary bladder cancer	6.4e-05	0.00412	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	6.39e-05	0.00412	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.33e-05	0.00408	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	5.9e-05	0.00381	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	5.89e-05	0.0038	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—UGT2B7—urinary bladder cancer	5.88e-05	0.00379	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.47e-05	0.00353	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	5.44e-05	0.00351	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP4B1—urinary bladder cancer	5.3e-05	0.00342	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	5.27e-05	0.0034	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	5.18e-05	0.00334	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	5.02e-05	0.00324	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—SLC19A1—urinary bladder cancer	5e-05	0.00323	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—IGF1—urinary bladder cancer	4.9e-05	0.00316	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PRSS3—urinary bladder cancer	4.87e-05	0.00314	CbGpPWpGaD
Valsartan—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	4.84e-05	0.00312	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—urinary bladder cancer	4.67e-05	0.00301	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	4.57e-05	0.00294	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTZ1—urinary bladder cancer	4.56e-05	0.00294	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HDAC4—urinary bladder cancer	4.46e-05	0.00287	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL2—urinary bladder cancer	4.39e-05	0.00283	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTO2—urinary bladder cancer	4.32e-05	0.00279	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NAT1—urinary bladder cancer	4.32e-05	0.00279	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.25e-05	0.00274	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—UGT2B7—urinary bladder cancer	3.95e-05	0.00255	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	3.95e-05	0.00255	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—TNF—urinary bladder cancer	3.93e-05	0.00254	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.91e-05	0.00252	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	3.9e-05	0.00251	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—TYMP—urinary bladder cancer	3.9e-05	0.00251	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	3.81e-05	0.00246	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	3.77e-05	0.00243	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.74e-05	0.00241	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	3.74e-05	0.00241	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GLI1—urinary bladder cancer	3.73e-05	0.00241	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	3.68e-05	0.00238	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.67e-05	0.00237	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP4B1—urinary bladder cancer	3.56e-05	0.00229	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NAT2—urinary bladder cancer	3.52e-05	0.00227	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	3.48e-05	0.00224	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.43e-05	0.00221	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SLC19A1—urinary bladder cancer	3.36e-05	0.00217	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PRSS3—urinary bladder cancer	3.27e-05	0.00211	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TNF—urinary bladder cancer	3.2e-05	0.00206	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	3.2e-05	0.00206	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.15e-05	0.00203	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	3.13e-05	0.00202	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	3.11e-05	0.002	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—RRM2—urinary bladder cancer	3.04e-05	0.00196	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CXCL8—urinary bladder cancer	3.01e-05	0.00194	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TP53—urinary bladder cancer	2.82e-05	0.00182	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ENO2—urinary bladder cancer	2.82e-05	0.00182	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—HPGDS—urinary bladder cancer	2.82e-05	0.00182	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.8e-05	0.00181	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTT1—urinary bladder cancer	2.73e-05	0.00176	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.69e-05	0.00173	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.63e-05	0.00169	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TYMP—urinary bladder cancer	2.62e-05	0.00169	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTZ1—urinary bladder cancer	2.6e-05	0.00168	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RBX1—urinary bladder cancer	2.56e-05	0.00165	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.56e-05	0.00165	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	2.54e-05	0.00164	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.51e-05	0.00162	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTO2—urinary bladder cancer	2.47e-05	0.00159	CbGpPWpGaD
Valsartan—ALB—Metabolism—NAT1—urinary bladder cancer	2.47e-05	0.00159	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.43e-05	0.00157	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TSC1—urinary bladder cancer	2.41e-05	0.00155	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NAT2—urinary bladder cancer	2.37e-05	0.00153	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JAG1—urinary bladder cancer	2.29e-05	0.00148	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NQO1—urinary bladder cancer	2.27e-05	0.00146	CbGpPWpGaD
Valsartan—ALB—Metabolism—UGT2B7—urinary bladder cancer	2.26e-05	0.00146	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.2e-05	0.00142	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	2.17e-05	0.0014	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	2.13e-05	0.00137	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.1e-05	0.00135	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—RRM2—urinary bladder cancer	2.04e-05	0.00132	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP4B1—urinary bladder cancer	2.03e-05	0.00131	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	2.02e-05	0.0013	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NAT1—urinary bladder cancer	2.02e-05	0.0013	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	1.99e-05	0.00128	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.99e-05	0.00128	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IFNA2—urinary bladder cancer	1.94e-05	0.00125	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.94e-05	0.00125	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.92e-05	0.00124	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC19A1—urinary bladder cancer	1.92e-05	0.00124	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTP1—urinary bladder cancer	1.89e-05	0.00122	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HPGDS—urinary bladder cancer	1.89e-05	0.00122	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ENO2—urinary bladder cancer	1.89e-05	0.00122	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.88e-05	0.00121	CbGpPWpGaD
Valsartan—ALB—Metabolism—PRSS3—urinary bladder cancer	1.87e-05	0.00121	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—S100B—urinary bladder cancer	1.85e-05	0.0012	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	1.85e-05	0.00119	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTT1—urinary bladder cancer	1.84e-05	0.00118	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.83e-05	0.00118	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.81e-05	0.00117	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—TYMS—urinary bladder cancer	1.76e-05	0.00114	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—RHOA—urinary bladder cancer	1.76e-05	0.00113	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTM1—urinary bladder cancer	1.74e-05	0.00112	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NCOR1—urinary bladder cancer	1.74e-05	0.00112	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.72e-05	0.00111	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.7e-05	0.0011	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	1.67e-05	0.00108	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NCOR1—urinary bladder cancer	1.67e-05	0.00108	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GPX1—urinary bladder cancer	1.67e-05	0.00107	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	1.66e-05	0.00107	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ERCC2—urinary bladder cancer	1.64e-05	0.00106	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL2—urinary bladder cancer	1.62e-05	0.00105	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	1.57e-05	0.00101	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.54e-05	0.000995	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—MTHFR—urinary bladder cancer	1.54e-05	0.000992	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	1.53e-05	0.000988	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NQO1—urinary bladder cancer	1.53e-05	0.000984	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.5e-05	0.000967	CbGpPWpGaD
Valsartan—ALB—Metabolism—TYMP—urinary bladder cancer	1.5e-05	0.000965	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.48e-05	0.000955	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL2—urinary bladder cancer	1.48e-05	0.000951	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TERT—urinary bladder cancer	1.47e-05	0.000948	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	1.46e-05	0.00094	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.44e-05	0.000926	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PLAU—urinary bladder cancer	1.38e-05	0.000887	CbGpPWpGaD
Valsartan—ALB—Metabolism—NAT2—urinary bladder cancer	1.35e-05	0.000872	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FGFR3—urinary bladder cancer	1.35e-05	0.00087	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ESR1—urinary bladder cancer	1.31e-05	0.000845	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.29e-05	0.000832	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTP1—urinary bladder cancer	1.27e-05	0.000821	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARG—urinary bladder cancer	1.25e-05	0.000804	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.23e-05	0.000794	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.23e-05	0.000792	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.22e-05	0.00079	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CREBBP—urinary bladder cancer	1.2e-05	0.000773	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	1.18e-05	0.000763	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.18e-05	0.000758	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	1.17e-05	0.000754	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	1.17e-05	0.000754	CbGpPWpGaD
Valsartan—ALB—Metabolism—RRM2—urinary bladder cancer	1.17e-05	0.000753	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CREBBP—urinary bladder cancer	1.15e-05	0.00074	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CREBBP—urinary bladder cancer	1.13e-05	0.000732	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IGF1—urinary bladder cancer	1.13e-05	0.000731	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—EGFR—urinary bladder cancer	1.13e-05	0.000728	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IGF1—urinary bladder cancer	1.12e-05	0.000722	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	1.12e-05	0.000722	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.11e-05	0.000714	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	1.1e-05	0.000709	CbGpPWpGaD
Valsartan—ALB—Metabolism—HPGDS—urinary bladder cancer	1.08e-05	0.000697	CbGpPWpGaD
Valsartan—ALB—Metabolism—ENO2—urinary bladder cancer	1.08e-05	0.000697	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.08e-05	0.000693	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—KRAS—urinary bladder cancer	1.07e-05	0.000687	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTT1—urinary bladder cancer	1.05e-05	0.000676	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RHOA—urinary bladder cancer	1.04e-05	0.00067	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	1.03e-05	0.000666	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.03e-05	0.000666	CbGpPWpGaD
Valsartan—ALB—Hemostasis—RHOA—urinary bladder cancer	1.03e-05	0.000662	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	9.82e-06	0.000633	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—urinary bladder cancer	9.81e-06	0.000633	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ERBB2—urinary bladder cancer	9.62e-06	0.00062	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—RRM2—urinary bladder cancer	9.56e-06	0.000616	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL8—urinary bladder cancer	9.12e-06	0.000588	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—HRAS—urinary bladder cancer	9.06e-06	0.000584	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ENO2—urinary bladder cancer	8.85e-06	0.000571	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	8.85e-06	0.000571	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.8e-06	0.000567	CbGpPWpGaD
Valsartan—ALB—Metabolism—NQO1—urinary bladder cancer	8.72e-06	0.000562	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2—urinary bladder cancer	8.72e-06	0.000562	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2—urinary bladder cancer	8.61e-06	0.000555	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	8.59e-06	0.000554	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTEN—urinary bladder cancer	8.56e-06	0.000552	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCND1—urinary bladder cancer	8.5e-06	0.000548	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.46e-06	0.000545	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.45e-06	0.000545	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	8.38e-06	0.00054	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—urinary bladder cancer	8.25e-06	0.000532	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1A—urinary bladder cancer	8.22e-06	0.00053	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTEN—urinary bladder cancer	8.2e-06	0.000529	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—EP300—urinary bladder cancer	8.16e-06	0.000526	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	8.05e-06	0.000519	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EP300—urinary bladder cancer	7.82e-06	0.000504	CbGpPWpGaD
Valsartan—ALB—Hemostasis—EP300—urinary bladder cancer	7.73e-06	0.000498	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SRC—urinary bladder cancer	7.6e-06	0.00049	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SRC—urinary bladder cancer	7.51e-06	0.000484	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.38e-06	0.000476	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTP1—urinary bladder cancer	7.27e-06	0.000469	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NQO1—urinary bladder cancer	7.14e-06	0.00046	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.03e-06	0.000454	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.92e-06	0.000446	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MYC—urinary bladder cancer	6.81e-06	0.000439	CbGpPWpGaD
Valsartan—ALB—Metabolism—TYMS—urinary bladder cancer	6.76e-06	0.000436	CbGpPWpGaD
Valsartan—ALB—Metabolism—NCOR1—urinary bladder cancer	6.68e-06	0.000431	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTM1—urinary bladder cancer	6.68e-06	0.000431	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGFR—urinary bladder cancer	6.67e-06	0.00043	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	6.59e-06	0.000425	CbGpPWpGaD
Valsartan—ALB—Metabolism—GPX1—urinary bladder cancer	6.4e-06	0.000413	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KRAS—urinary bladder cancer	6.3e-06	0.000406	CbGpPWpGaD
Valsartan—ALB—Metabolism—ERCC2—urinary bladder cancer	6.28e-06	0.000405	CbGpPWpGaD
Valsartan—ALB—Hemostasis—KRAS—urinary bladder cancer	6.22e-06	0.000401	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.04e-06	0.000389	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	5.95e-06	0.000384	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTHFR—urinary bladder cancer	5.9e-06	0.000381	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.76e-06	0.000371	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	5.75e-06	0.000371	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TP53—urinary bladder cancer	5.6e-06	0.000361	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TYMS—urinary bladder cancer	5.53e-06	0.000357	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TP53—urinary bladder cancer	5.53e-06	0.000357	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—EP300—urinary bladder cancer	5.48e-06	0.000354	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	5.47e-06	0.000353	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	5.47e-06	0.000353	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HRAS—urinary bladder cancer	5.35e-06	0.000345	CbGpPWpGaD
Valsartan—ALB—Hemostasis—HRAS—urinary bladder cancer	5.29e-06	0.000341	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPX1—urinary bladder cancer	5.24e-06	0.000338	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	5.14e-06	0.000332	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	4.83e-06	0.000312	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARG—urinary bladder cancer	4.79e-06	0.000309	CbGpPWpGaD
Valsartan—ALB—Metabolism—CREBBP—urinary bladder cancer	4.6e-06	0.000297	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARG—urinary bladder cancer	3.92e-06	0.000253	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—urinary bladder cancer	3.77e-06	0.000243	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	3.77e-06	0.000243	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTEN—urinary bladder cancer	3.28e-06	0.000212	CbGpPWpGaD
Valsartan—ALB—Metabolism—EP300—urinary bladder cancer	3.13e-06	0.000202	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	3.08e-06	0.000199	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.69e-06	0.000173	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.56e-06	0.000165	CbGpPWpGaD
